Journal of the Peripheral Nervous System最新文献

{"title":"Broadening Research Priorities in Peripheral Neuropathy: A Response to “A Call to Action for Peripheral Neuropathy Research Funding—Time to Consolidate Funding Under One NIH Initiative?”","authors":"Lien-Chung Wei, Hsien-Jane Chiu","doi":"10.1111/jns.70003","DOIUrl":"10.1111/jns.70003","url":null,"abstract":"","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurological Performance and Clinical Outcomes Related to Patients With Oropouche-Associated Guillain–Barré Syndrome","authors":"Frank D. Martos-Benítez,&nbsp;Iliovanys Betancourt-Plaza,&nbsp;Isleidys Osorio-Carmenates,&nbsp;Nadieska J. González-Martínez,&nbsp;Ileana Moráles-Suárez,&nbsp;Carilda E. Peña-García,&nbsp;Yudeily L. Pérez-Matos,&nbsp;Zurina Lestayo-O'Farrill,&nbsp;José R. de Armas-Fernández,&nbsp;Raysa C. Cárdenas-González,&nbsp;Judet Izquierdo-Castañeda,&nbsp;Ernesto Sánchez-de la Rosa,&nbsp;Versis Orama-Requejo","doi":"10.1111/jns.12683","DOIUrl":"10.1111/jns.12683","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>A recent study reported that Oropouche virus (OROV) infection may play a role in the etiology of Guillain–Barré syndrome. We aimed to identify the neurological performance, disease-modifying therapies, and clinical outcomes related to patients with Oropouche-associated Guillain–Barré syndrome admitted to the critical care unit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was an analysis of 210 patients diagnosed with Guillain–Barré syndrome and suspicion of Oropouche viral infection admitted to the critical care units from June 2024 to September 2024 using the national administrative healthcare data. OROV was identified by reverse-transcriptase–polymerase-chain-reaction. Patients with Guillain–Barré syndrome and Oropouche infection were compared with those without Oropouche infection in terms of demography features, neurological performance, disease-modifying therapies, and clinical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most patients had a severe disease. Mechanical ventilation was required in 28.6%. Overall mortality rate was 14.3%. The median time from onset of weakness to intensive care unit discharge, and the median time from hospital admission to intensive care unit discharge was 18 days (IQR: 13–24.3 days) and 13 days (IQR: 9–19 days), respectively. Oropouche viral infection was detected in 43 (20.5%) patients. There were no differences among patients with and without Oropouche viral infection regarding general characteristics, neurological performance, disease-modifying therapies, and outcomes. After adjusting for confounders in multivariate logistic regression analysis, Oropouche viral infection (OR: 1.94; 95% CI: 0.72–5.20; <i>p</i> = 0.189) was not related to increased mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>Oropouche viral infection does not modify the clinical course, disease severity, and outcomes of patients with Guillain–Barré syndrome.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143033390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A call to action for peripheral neuropathy research funding—Time to consolidate funding under one NIH initiative?","authors":"Stéphanie A. Eid,&nbsp;Kristy L. Townsend,&nbsp;Vincenza Spallone,&nbsp;Daniela M. Menichella,&nbsp;Emily J. Koubek,&nbsp;Eva L. Feldman","doi":"10.1111/jns.12681","DOIUrl":"10.1111/jns.12681","url":null,"abstract":"&lt;p&gt;Peripheral neuropathies (PNs) pose a significant clinical challenge in the field of neurological disorders, with a prevalence of 2.4% in the general population that rises with age to over 8% in patients aged 55 years and older.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Symmetrical, distal-to-proximal axonal loss is the most common form of PN and accounts for most cases.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; It is characterized by damage to the peripheral nerves that typically, especially for diabetes (the leading cause of PN), impacts small-diameter axons beginning in the feet and progresses proximally in a length-dependent manner. PN results in a range of debilitating symptoms such as numbness, tingling, weakness, as well as burning or shooting pain.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Along with these painful symptoms, patients may experience depression, anxiety, and sleep disturbances.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; As PN progresses, individuals may present with diminished sensation to mechanical and thermal stimuli, making it challenging to perceive or effectively heal injuries or trauma, which increases the risk of non-healing ulcers. In severe cases, the cumulative effects of sensation loss and non-healing ulcers can necessitate lower limb amputations.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; In fact, patients with PN are almost four times at greater risk of undergoing lower-limb amputation than those without.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; Additionally, PN also leads to an increased risk of falls due to compromised balance and proprioception, further exacerbating the potential for injury and disability in affected individuals. PN likely impacts far more tissues and organs than previously appreciated.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; Data now indicate diabetic PN exists in the muscle, liver, adipose tissue, pancreas, gastrointestinal tract, and heart.&lt;span&gt;&lt;sup&gt;9-17&lt;/sup&gt;&lt;/span&gt; PN profoundly impacts the lives of patients, with limited therapeutic options to mitigate pain symptoms, prevent progression, or regenerate lost axons.&lt;/p&gt;&lt;p&gt;While clinical presentations may appear similar, PN can result from a range of causes, including both inherited and acquired conditions. Hereditary neuropathies (HN), such as Charcot–Marie-Tooth (CMT) disease and hereditary sensory and autonomic neuropathies, comprise a diverse group of inherited PN disorders, with an overall prevalence of 1:2500.&lt;span&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/span&gt; These differ in their inheritance patterns (autosomal dominant, recessive, or X-linked), electrophysiological characteristics (demyelinating, axonal, or intermediate), and clinical features. While not as common as the other PN types, HN highlight the importance of genetic factors in neuropathic disorders.&lt;/p&gt;&lt;p&gt;Of the acquired neuropathies, diabetic peripheral neuropathy (DPN) is the most prevalent, accounting for 32%–53% of total cases.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; As cases of diabetes are expected to rise from 537 to 783 million by 2045, DPN, which affects 50% or more of patients and increases in frequency with di","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling","authors":"Grace Swart,&nbsp;Michael P. Skolka,&nbsp;Shahar Shelly,&nbsp;Richard A. Lewis,&nbsp;Jeffrey A. Allen,&nbsp;Divyanshu Dubey,&nbsp;Zhiyv Niu,&nbsp;Judith Spies,&nbsp;Ruple S. Laughlin,&nbsp;Smathorn Thakolwiboon,&nbsp;Ashley R. Santilli,&nbsp;Hebatallah Rashed,&nbsp;Igal Mirman,&nbsp;Alexander Swart,&nbsp;Sarah E. Berini,&nbsp;Kamal Shouman,&nbsp;Marcus V. Pinto,&nbsp;Michelle L. Mauermann,&nbsp;John R. Mills,&nbsp;P. James B. Dyck,&nbsp;William S. Harmsen,&nbsp;Jay Mandrekar,&nbsp;Christopher J. Klein","doi":"10.1111/jns.12682","DOIUrl":"10.1111/jns.12682","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is difficult to distinguish from mimicking disorders, with misdiagnosis resulting in IVIG overutilization. We evaluate a clinical-electrophysiological model to facilitate CIDP versus mimic neuropathy prediction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021 CIDP guidelines we derived 26 clinical and 144 nerve conduction variables. The model was generated and validated utilizing total CIDP (<i>n</i> = 129) and mimics (<i>n</i> = 309); including (1) IgG4-nodopathies; (2) POEMS (polyneuropathy–organomegaly–endocrinopathy–monoclonal protein-skin changes); (3) anti-myelin-associated-glycoprotein; (4) paraneoplastic; (5) Waldenström B-cell lymphoma; (6) diabetic neuropathies; (7) amyloidosis; (8) Charcot–Marie–Tooth; (9) motor neuropathies/neuronopathies; and (10) idiopathic-inflammatory-myopathies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We analyzed 9282 clinical and 51 408 electrophysiological data points. Univariate analysis identified 11 of 26 clinical variables with significant odds ratios. A multivariate regression model using four clinical and two electrophysiologic variables achieved 93% area-under-curve (95% CI 91–95): progression over 8 weeks (OR 40.66, 95% CI 5.31–311.36), absent autonomic involvement (OR 17.82, 95% CI 2.93–108.24), absent muscle atrophy (OR 16.65, 95% CI 3.27–84.73), proximal weakness (OR 3.63, 95% CI 1.58–8.33), ulnar motor conduction velocity slowing &lt; 35.7 m/s (OR 5.21, 95% CI 2.13–12.76), and ulnar motor conduction block (OR 13.37, 95% CI 2.47–72.40). A web-based probability calculator (https://news.mayocliniclabs.com/cidp-calculator/) was developed, with 100% sensitivity and 68% specificity at a 92% probability threshold. Specificity improved to 93% when considering “red flags,” electrophysiologic criteria, and laboratory testing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>A probability calculator using clinical electrophysiological variables assists CIDP differentiation from mimics, with scores below 92% unlikely to have CIDP. The highest specificity is achieved by considering clinical “red flags,” electrophysiologic demyelination, and laboratory testing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimal invasive biopsies are highly sensitive for amyloid detection in hereditary transthyretin amyloidosis with polyneuropathy","authors":"Luca Leonardi,&nbsp;Clovis Adam,&nbsp;Guillemette Beaudonnet,&nbsp;Diane Beauvais,&nbsp;Cécile Cauquil,&nbsp;Adeline Not,&nbsp;Olivier Morassi,&nbsp;Olivier Trassard,&nbsp;Andoni Echaniz-Laguna,&nbsp;David Adams,&nbsp;Céline Labeyrie","doi":"10.1111/jns.12680","DOIUrl":"10.1111/jns.12680","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To assess the effectiveness of labial minor salivary gland biopsy (LSGB) alone or in combination with punch skin biopsy (SB) for the detection of amyloid deposits in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this single-center retrospective study, Congo red staining of minimal invasive LSGB (4 mm) and SB (3 mm) was assessed in ATTRv-PN patients consecutively evaluated between 2012 and 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Histopathological data of 171 ATTRv-PN, including 49 early-onset p.Val50Met, 58 late-onset p.Val50Met, and 64 non-p.Val50Met, were reviewed. LSGB and SB identified amyloid deposits in 123/171 (72%) and 131/171 (77%) patients respectively (<i>p</i> = 0.2). Combining LSGB and SB increased the amyloid detection rate to 150/171 (88%), especially in late-onset p.Val50Met (48/58 [83%]) and non-p.Val50Met patients (55/64 [86%]). LSGB and SB have a similar rate of detection of amyloid depositions in early onset p.Val50Met patients (94%). Also, the LSGB/SB combination identified amyloidosis in 89% (55/62) of early-stage ATTRv-PN patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In our study, combining LSGB and SB allowed the detection of amyloid deposits in 88% of ATTRv-PN patients. LSGB/SB analysis may be of major interest to confirm entry in the disease at very early-stage ATTRv-PN, with implications in disease-modifying treatment initiation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ofatumumab for treating autoimmune nodopathy","authors":"Jianian Hu,&nbsp;Yongsheng Zheng,&nbsp;Chong Sun,&nbsp;Jian Sun,&nbsp;Jianying Xi,&nbsp;Sushan Luo,&nbsp;Kai Qiao,&nbsp;Chongbo Zhao,&nbsp;Jie Lin","doi":"10.1111/jns.12679","DOIUrl":"10.1111/jns.12679","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>To investigate the treatment of ofatumumab in autoimmune nodopathy (AN).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An open-label, prospective, observational study was conducted in patients with AN. The regimen was 20 mg ofatumumab subcutaneously on day 0, 7, 14, 28, and subsequently every 4 weeks in a total of 24 weeks. The primary endpoint of the study was the proportion of patients with confirmed clinical improvement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All of the eight patients (100%) improved at Week 24. The median time to improvement was 8 (IQR: 7–10) weeks. The four patients previously treated with rituximab and two with irregular injections of ofatumumab (OFA) improved. At Week 24, the adjusted INCAT score, MRC sum score, cI-RODS, and grip strength in nondominant hand significantly improved from baseline. In nerve conduction studies, all of the six patients with available data (100%) improved. The median sNfL significantly reduced from baseline at Week 8. Anti-paranodal antibody in seven patients with anti-NF155 antibodies reduced from baseline at Week 20. In seven of the eight patients, CD19+ B cells were significantly reduced at Week 4. No serious adverse events were reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>The regimen was 20 mg ofatumumab subcutaneously on day 0, 7, 14, 28, and every 4 weeks from Week 4, in a total of 24 weeks. The ofatumumab therapy may provide a more convenient and safer treatment for patients with AN, while serving as an effective alternative for those who did not respond to rituximab.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts of the 35th Annual Meeting of the Japanese Peripheral Nerve Society (JPNS)","authors":"","doi":"10.1111/jns.12678","DOIUrl":"10.1111/jns.12678","url":null,"abstract":"<p>September 6–7, 2024</p><p>Kagoshima, Japan</p><p>President of JPNS: Ken-ichi Kaida</p><p>Congress Chair: Hiroshi Takashima</p><p>Scientific Committee (Editors of JPNS): Kazunori Sango, Yoshiki Sekijima, Shigeru Kurimoto, Ayato Hayashi, Ryosuke Ikeguchi, Norimasa Iwasaki, Haruki Koike, Norito Kokubun, Hiroki Mizukami, Yasumasa Nishiura, Akinori Sakai, Kazuma Sugie, Hiroshi Takashima</p><p>Organizing Committee: Hiroshi Takashima, Akihiro Hashiguchi, Yujiro Higuchi, Masahiro Ando</p><p>JPNS Editorial Staff: Kana Shimada</p><p>JPNS Secretariat: Munehisa Izuno, Haruna Tanaka</p><p>Organizing Secretariat: www.congre.co.jp/jpns2024/</p>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 S1","pages":"S3-S17"},"PeriodicalIF":3.9,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jns.12678","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Korean version of inflammatory Rasch-built Overall Disability Scale in patients with inflammatory neuropathy","authors":"Woohee Ju,&nbsp;Young Gi Min,&nbsp;Jong Su Kim,&nbsp;Jiwon Choi,&nbsp;Jiwon Lee,&nbsp;Seok-Jin Choi,&nbsp;Sung-Min Kim,&nbsp;Yoon-Ho Hong,&nbsp;Jung-Joon Sung","doi":"10.1111/jns.12676","DOIUrl":"10.1111/jns.12676","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>The Inflammatory Rasch-built Overall Disability Scale (I-RODS) is an effective activity measure for use in inflammatory peripheral neuropathy. The aim of this study was to validate the Korean version of the I-RODS in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), anti-myelin-associated glycoprotein (MAG) neuropathy, and autoimmune nodopathy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 120 patients underwent clinical evaluations, which included the I-RODS, Inflammatory Neuropathy Cause and Treatment (INCAT) assessment, and Jamar grip strength (kg) measurement. Follow-up assessments were performed for 83 patients during their regular clinic visits. To estimate the test–retest reliability of the I-RODS, the scale was reapplied to a subset of 16 patients within 2–7 days of the initial test. Overall, reliability, validity, and responsiveness of the I-RODS were evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Internal consistency was good, as indicated by a person separation index of 0.966. The raw and standardized Cronbach's alpha values were both 0.974. The test–retest reliability analyzed using the intraclass correlation coefficient (ICC) was also high (ICC = 0.972). The I-RODS showed a strong correlation with INCAT scores (<i>ρ</i> = −0.81, <i>p</i> &lt; .001) and a moderate correlation with grip strength (<i>ρ</i> = 0.61, <i>p</i> &lt; .001). Furthermore, the sensitivity for detecting clinically meaningful improvement was highest for grip strength (60.4%) followed by I-RODS (52.1%), while for capturing deterioration, it was highest for I-RODS (80.0%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>The Korean version of the I-RODS is a reliable and valid tool for measuring disability in patients with inflammatory neuropathy. The I-RODS is useful for both clinical practice and research applications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital nerve reconstruction with a new composite silk fibroin nerve conduit","authors":"Olga Politikou,&nbsp;Florian S. Frueh,&nbsp;Martina Greminger,&nbsp;Inga S. Besmens,&nbsp;Giuliano Freddi,&nbsp;Antonio Alessandrino,&nbsp;Maurizio Calcagni","doi":"10.1111/jns.12675","DOIUrl":"10.1111/jns.12675","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Peripheral nerve injuries often require bridging when direct repair is not feasible. Nerve autografts are the gold standard, but they can lead to donor site morbidity. Silk fibroin-based nerve conduits, like the novel SILKBridge, offer a promising alternative. This pilot study evaluates the mid-term outcomes of the first in-human digital nerve reconstruction using the SILKBridge, focusing on sensory recovery, complication rates, patient-reported outcomes, and biological integration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study included four patients with digital nerve defects reconstructed using the SILKBridge. Clinical assessments included two-point discrimination, Semmes–Weinstein monofilament testing, and pain evaluation using the Numeric Rating Scale. Sonographic assessments were also performed to evaluate the conduit's biointegration and potential complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At a mean follow-up of 32 months, all patients demonstrated satisfactory sensory recovery and reported minimal to no pain. Sonographic assessments confirmed effective biointegration with no signs of inflammation or scarring.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>The mid-term evaluation of the first in-human digital nerve reconstruction with the SILKBridge revealed safety, efficiency, and favorable biocompatibility properties. Further studies with larger cohorts are needed to validate these findings and compare them with other nerve repair methods.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dorsal root ganglia CSF1+ neuronal subtypes have different impact on macrophages and microglia after spared nerve injury","authors":"Andreea Violeta Grosu,&nbsp;Roxana-Olimpia Gheorghe,&nbsp;Alexandru Filippi,&nbsp;Alexandru Florian Deftu,&nbsp;Manon Isler,&nbsp;Marc Suter,&nbsp;Violeta Ristoiu","doi":"10.1111/jns.12674","DOIUrl":"10.1111/jns.12674","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Colony-stimulating factor 1 (CSF1) is a growth factor secreted by dorsal root ganglia (DRG) neurons important for DRG macrophages and spinal cord (SC) microglia injury-induced proliferation and activation, specifically released after spared nerve injury (SNI). In this study, we investigated if SNI-induced CSF1 expression and perineuronal rings of macrophages around mouse DRG neurons vary between L3-L5 DRG and with the neuronal type, and if the CSF1⁺ neuronal projections at the SC dorsal horns were associated with an increased microglial number in the corresponding laminae.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Seven days after surgery, L3-L5 DRG as well as their corresponding segments at the SC level were collected, frozen, and cut. DRG sections were double-immunostained using antibodies against CSF1 and NF200, CGRP or IB4, while SC sections were immunostained using a fluorescent Nissl Stain and analyzed for CX3CR1-GFP microglia number and distribution by an <i>in-house</i> ImageJ Plug-in.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our results showed that SNI-induced CSF1 expression was common for all subtypes of mouse DRG neurons, being responsible for attracting more resident macrophages around them in a DRG-dependent manner, with L4 showing the stronger response and CSF1⁺/NF200⁺ neurons showing the highest incidence. Even though the total number of microglia in the SC ipsilateral dorsal horns increased after SNI, the increase at their specific laminar projection sites did not mirror the incidence of DRG neuronal subtypes among CSF1⁺ neurons.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>Taken together, these results contribute to a more comprehensive understanding of the connection between CSF1 and macrophage/microglia response after SNI and emphasize the importance of considering L3-L5 DRG individually when investigating SNI-neuropathic pain pathogenesis in mice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"29 4","pages":"514-527"},"PeriodicalIF":3.9,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}